Advantages of the Ultralow-dose Hormonal Menopausal Therapy: An Ample Opportunity with Minimal Risks

For citation: Apetov S.S., Apetova V.V. Advantages of the Ultralow-dose Hormonal Menopausal Therapy: An Ample Opportunity with Minimal Risks. Doctor.Ru. 2021; 20(8): 41–47. (in Russian). DOI: 10.31550/1727-2378-2021-20-8-41-47
20 September 00:00
S.S. Apetov V.V. Apetova

Objective of the Review: To analyse the efficacy and safety of the ultralow-dose menopausal hormonal therapy (MHT).

Key Points. In developed countries, the life expectancy is growing and the issue of improved quality of life of elderly women is becoming quite acute. On the average, a third (or a half for early menopause) of a modern woman’s life falls on the post-menopause period. Termination of oestrogen synthesis in ovaries during menopause is associated with marked reduction in the quality of life, development of vasomotor symptoms, sleep disturbances, accelerated skin ageing, an increased risk of cardiovascular pathologies and a number of somatic disorders, urinogenital atrophy, osteoporosis, and cognitive disorders. MHT is a proven and efficient means of quality of life improvement; however, the safety of sex hormone therapy in elderly women is still a topical issue. In this article, we are discussing the efficacy and safety of oral MHT drug containing 0.5 mg of 17β-estradiol and 2.5 mg of didrogesteron.

Conclusion. The advent of ultralow-dose MHT drugs allowed significantly reducing the number of side effects from sex hormone therapy during post-menopause vs. side effects from higher doses of estradiol with comparable clinical effects.

Contributions: Apetov, S.S. — selection and analysis of references, text of the article, approval of the manuscript for publication; Apetova, V.V. — analysis of references, final article editing. 

Conflict of interest: The authors declare that they do not have any conflict of interests.

S.S. Apetov (Corresponding author) — Endocrine health Centre LLC; 58A Sverdlovskiy Prosp., Chelyabinsk, Russian Federation 454080. E-mail: apetov@rambler.ru

V.V. Apetova — Endocrine health Centre LLC; 58A Sverdlovskiy Prosp., Chelyabinsk, Russian Federation 454080. E-mail: stella911@yandex.ru


Received: 31.08.2021

Accepted: 09.09.2021

20 September 00:00
  1. Hodis H.N., Collins P., Mack W.J. et al. The timing hypothesis for coronary heart disease prevention with hormone therapy: past, present and future in perspective. Climacteric. 2012; 15(3): 217–28. DOI: 10.3109/13697137.2012.656401
  2. Stute P., Becker H.G., Bitzer J. et al. Ultra-low dose — new approaches in menopausal hormone therapy. Climacteric. 2015; 18(2): 182–6. DOI: 10.3109/13697137.2014.975198
  3. Baber R.J., Panay N., Fenton A.; IMS Writing Group. 2016 IMS Recommendations on women's midlife health and menopause hormone therapy. Climacteric. 2016; 19(2): 109–50. DOI: 10.3109/13697137.2015.1129166
  4. Serov V.N., Yureneva S.V., eds. Algorithms for the use of menopausal hormone therapy in women during the peri- and postmenopausal period. Joint position of experts ROAG, RAM, AGE, RAOP. Obstetrics and Gynecology. 2021; 3: 210–21. (in Russian). DOI: 10.18565/aig.2021.3.210-221
  5. Politi M.C., Schleinitz M.D., Col N.F. Revisiting the duration of vasomotor symptoms of menopause: a meta-analysis. J. Gen. Intern. Med. 2008; 23(9): 1507–13. DOI: 10.1007/s11606-008-0655-4
  6. Notelovitz M., Lenihan J.P., McDermott M. et al. Initial 17beta-estradiol dose for treating vasomotor symptoms. Obstet. Gynecol. 2000; 95(5): 726–31. DOI: 10.1016/s0029-7844(99)00643-2
  7. Song Y., Xu W., Chatooah N.D. et al. Comparison of low dose versus ultra-low dose hormone therapy in menopausal symptoms and quality of life in perimenopause women. Gynecol. Endocrinol. 2020; 36(3): 252–6. DOI: 10.1080/09513590.2019.1666815
  8. Stevenson J.C., Durand G., Kahler E. et al. Oral ultra-low dose continuous combined hormone replacement therapy with 0.5 mg 17β-oestradiol and 2.5 mg dydrogesterone for the treatment of vasomotor symptoms: results from a double-blind, controlled study. Maturitas. 2010; 67(3): 227–32. DOI: 10.1016/j.maturitas.2010.07.002
  9. Ren M., Ruan X., Gu L. et al. Ultra-low-dose estradiol and dydrogeste­rone: a phase III study for vasomotor symptoms in China. Climacteric. 2021 Aug 17: 1–7. DOI: 10.1080/13697137.2021.1956894. Online ahead of print
  10. Tune J.D., Goodwill A.G., Sassoon D.J. et al. Cardiovascular consequences of metabolic syndrome. Transl. Res. 2017; 183: 57–70. DOI: 10.1016/j.trsl.2017.01.001
  11. Gluvic Z., Zaric B., Resanovic I. et al. Link between metabolic syndrome and insulin resistance. Curr. Vasc. Pharmacol. 2017; 15(1): 30–9. DOI: 10.2174/1570161114666161007164510
  12. Patni R., Mahajan A. The metabolic syndrome and menopause. J. Midlife Health. 2018; 9(3): 111–12. DOI: 10.4103/0976-7800.241951
  13. de Villiers T.J., Pines A., Panay N. et al.; International Menopause Society. Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric. 2013; 16(3): 316–37. DOI: 10.3109/13697137.2013.795683
  14. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. The Writing Group for the PEPI trial. JAMA. 1995; 273(3): 199–208
  15. Kwok S., Selby P.L., McElduff P. et al. Progestogens of varying androgenicity and cardiovascular risk factors in postmenopausal women receiving oestrogen replacement therapy. Clin. Endocrinol. 2004; 61: 760–7. DOI: 10.1111/j.1365-2265.2004.02166.x
  16. Jiang Y., Tian W. The effects of progesterones on blood lipids in hormone replacement therapy. Lipids Health Dis. 2017; 16(1): 219. DOI: 10.1186/s12944-017-0612-5
  17. Mantel-Teeuwisse A.K., Kloosterman J.M., Maitland-van der Zee A.H. et al. Drug-induced lipid changes: a review of the unintended effects of some commonly used drugs on serum lipid levels. Drug Saf. 2001; 24(6): 443–56. DOI: 10.2165/00002018-200124060-00003
  18. Naessen T., Rodriguez-Macias K., Lithell H. Serum lipid profile improved by ultra-low doses of 17 beta-estradiol in elderly women. J. Clin. Endocrinol. Metab. 2001; 86(6): 2757–62. DOI: 10.1210/jcem.86.6.7524
  19. Anagnostis P., Bitzer J., Cano A. et al. Menopause symptom management in women with dyslipidemias: an EMAS clinical guide. Maturitas. 2020; 135: 82–8. DOI: 10.1016/j.maturitas.2020.03.007
  20. Matsui S., Yasui T., Tani A. et al. Effect of ultra-low-dose estradiol and dydrogesterone on arterial stiffness in postmenopausal women. Climacteric. 2014; 17(2): 191–6. DOI: 10.3109/13697137.2013.856399
  21. De Villiers T.J. The role of menopause hormone therapy in the management of osteoporosis. Climacteric. 2015; 18(suppl.2): S19–31. DOI: 10.3109/13697137.2015.1099806
  22. Prestwood K.M., Kenny A.M., Kleppinger A. et al. Ultralow-dose micronized 17beta-estradiol and bone density and bone metabolism in older women: a randomized controlled trial. JAMA. 2003; 290(8): 1042–8. DOI: 10.1001/jama.290.8.1042
  23. Ettinger B., Ensrud K.E., Wallace R. et al. Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial. Obstet. Gynecol. 2004; 104(3): 443–51. DOI: 10.1097/01.AOG.0000137833.43248.79
  24. Gambacciani M., Cappagli B., Ciaponi M. et al. Ultra low-dose hormone replacement therapy and bone protection in postmenopausal women. Maturitas. 2008; 59(1): 2–6. DOI: 10.1016/j.maturitas.2007.10.007
  25. Rossouw J.E., Anderson G.L., Prentice R.L. et al.; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002; 288(3): 321–33. DOI: 10.1001/jama.288.3.321
  26. Dall G.V., Britt K.L. Estrogen effects on the mammary gland in early and late life and breast cancer risk. Front. Oncol. 2017; 7: 110. DOI: 10.3389/fonc.2017.00110
  27. Lima S.M., Kehm R.D., Terry M.B. Global breast cancer incidence and mortality trends by region, age-groups, and fertility patterns. EClinicalMedicine. 2021; 38: 100985. DOI: 10.1016/j.eclinm.2021.100985
  28. Pfeiffer R.M., Webb-Vargas Y., Wheeler W. et al. Proportion of U.S. trends in breast cancer incidence attributable to long-term changes in risk factor distributions. Cancer Epidemiol. Biomarkers Prev. 2018; 27(10): 1214–22. DOI: 10.1158/1055-9965.EPI-18-0098
  29. Lima S.M., Kehm R.D., Swett K. et al. Trends in parity and breast cancer incidence in US women younger than 40 years from 1935 to 2015. JAMA Netw. Open. 2020; 3(3): e200929. DOI: 10.1001/jamanetworkopen.2020.0929
  30. Geisler J. Breast cancer tissue estrogens and their manipulation with aromatase inhibitors and inactivators. J. Steroid Biochem. Mol. Biol. 2003; 86(3–5): 245–53. DOI: 10.1016/s0960-0760(03)00364-9
  31. Wang S., Paris F., Sultan C.S. et al. Recombinant cell ultrasensitive bioassay for measurement of estrogens in postmenopausal women. J. Clin. Endocrinol. Metab. 2005; 90(3): 1407–13. DOI: 10.1210/jc.2004-0766
  32. O'Neill J.S., Elton R.A., Miller W.R. Aromatase activity in adipose tissue from breast quadrants: a link with tumour site. Br. Med. J. (Clin. Res. Ed.). 1988; 296(6624): 741–3. DOI: 10.1136/bmj.296.6624.741
  33. Bulun S.E., Sharda G., Rink J. et al. Distribution of aromatase P450 transcripts and adipose fibroblasts in the human breast. J. Clin. Endocrinol. Metab. 1996; 81(3): 1273–7. DOI: 10.1210/jcem.81.3.8772611
  34. Mousa N.A., Crystal P., Wolfman W.L. et al. Aromatase inhibitors and mammographic breast density in postmenopausal women receiving hormone therapy. Menopause. 2008; 15: 875–84. DOI: 10.1097/gme.0b013e31816956c3
  35. Tworoger S.S., Missmer S.A., Barbieri R.L. et al. Plasma sex hormone concentrations and subsequent risk of breast cancer among women using postmenopausal hormones. J. Natl. Cancer Inst. 2005; 97(8): 595–602. DOI: 10.1093/jnci/dji099
  36. Hou N., Hong S., Wang W. et al. Hormone replacement therapy and breast cancer: heterogeneous risks by race, weight, and breast density. J. Natl. Cancer Inst. 2013; 105(18): 1365–72. DOI: 10.1093/jnci/djt207
  37. Lundström E., Bygdeson M., Svane G.E. et al. Neutral effect of ultra-low-dose continuous combined estradiol and norethisterone acetate on mammographic breast density. Climacteric. 2007; 10(3): 249–56. DOI: 10.1080/13697130701385805
  38. Lyytinen H., Pukkala E., Ylikorkala O. Breast cancer risk in postmenopausal women using estrogen-only therapy. Obstet. Gynecol. 2006; 108(6): 1354–60. DOI: 10.1097/01.AOG.0000241091.86268.6e
  39. Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet. 2019; 394(10204): 1159–68. DOI: 10.1016/ S0140-6736(19)31709-X
  40. Lyytinen H., Pukkala E., Ylikorkala O. Breast cancer risk in post­menopausal women using estradiol-progestogen therapy. Obstet. Gynecol. 2009; 113(1): 65–73. DOI: 10.1097/AOG.0b013e31818e8cd6
  41. Fournier A., Berrino F., Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res. Treat. 2008; 107(1): 103–11. DOI: 10.1007/s10549-007-9523-x
  42. Fournier A., Mesrine S., Dossus L. et al. Risk of breast cancer after stopping menopausal hormone therapy in the E3N cohort. Breast Cancer Res. Treat. 2014; 145(2): 535–43. DOI: 10.1007/s10549-014-2934-6
  43. Bergeron C., Ferenczy A. Endometrial safety of continuous combined hormone replacement therapy with 17beta-oestradiol (1 or 2 mg) and dydrogesterone. Maturitas. 2001; 37(3): 191–9. DOI: 10.1016/s0378-5122(00)00176-6
  44. Bergeron C., Nogales F.F., Rechberger T. et al. Ultra low dose continuous combined hormone replacement therapy with 0.5 mg 17beta-oestradiol and 2.5 mg dydrogesterone: protection of the endometrium and amenorrhoea rate. Maturitas. 2010; 66(2): 201–5. DOI: 10.1016/j.maturitas.2010.03.007
  45. Naessen T., Rodriguez-Macias K. Endometrial thickness and uterine diameter not affected by ultralow doses of 17beta-estradiol in elderly women. Am. J. Obstet. Gynecol. 2002; 186(5): 944–7. DOI: 10.1067/mob.2002.122143
  46. El Khoudary S.R., Zhao Q., Venugopal V. et al. Effects of hormone therapy on heart fat and coronary artery calcification progression: secondary analysis from the KEEPS Trial. J. Am. Heart Assoc. 2019; 8(15): e012763. DOI: 10.1161/JAHA.119.012763
  47. de Vries C.S., Bromley S.E., Farmer R.D. Myocardial infarction risk and hormone replacement: differences between products. Maturitas. 2006; 53(3): 343–50. DOI: 10.1016/j.maturitas.2005.06.004
  48. Crandall C.J., Hovey K.M., Andrews C. et al. Comparison of clinical outcomes among users of oral and transdermal estrogen therapy in the Women's Health Initiative Observational Study. Menopause. 2017; 24(10): 1145–53. DOI: 10.1097/GME.0000000000000899
  49. Carrasquilla G.D., Frumento P., Berglund A. et al. Postmenopausal hormone therapy and risk of stroke: a pooled analysis of data from population-based cohort studies. PLoS Med. 2017; 14(11): e1002445. DOI: 10.1371/journal.pmed.1002445
  50. Kareva E.N. Thrombosis and gestagens. Doctor.Ru. 2019; 7(162): 57–64. (in Russian). DOI: 10.31550/1727-2378-2019-162-7-57-64
  51. Piróg M., Jach R., Kacalska-Janssen O. Differential effect of the ultra-low dose and standard estrogen plus dydrogesterone therapy on thrombin generation and fibrinolysis in postmenopausal women. Acta Obstet. Gynecol. Scand. 2017; 96(12): 1438–45. DOI: 10.1111/aogs.13239
  52. Canonico M., Oger E., Plu-Bureau G. et al.; Estrogen and Thromboembolism Risk (ESTHER) Study Group. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation. 2007; 115(7): 840–5. DOI: 10.1161/CIRCULATIONAHA.106.642280
  53. Vinogradova Y., Coupland C., Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ. 2019; 364: k4810. DOI: 10.1136/bmj.k4810
  54. Tsiligiannis S., Wick-Urban B.C., van der Stam J. et al. Efficacy and safety of a low-dose continuous combined hormone replacement therapy with 0.5 mg 17β-estradiol and 2.5 mg dydrogesterone in subgroups of postmenopausal women with vasomotor symptoms. Maturitas. 2020; 139: 20–6. DOI: 10.1016/j.maturitas.2020.05.002


20 September 00:00
A New Issue of Doctor.Ru Gynecology, Vol. 20 No. 8 (2021), Published

Find original articles and reviews covering various aspects of reproductive genetics, gynecology, gynecologic oncology, cross-disciplinary approach and the interview with Professor Dmitry Yurievich Trofimov

31 August 13:19
A New Issue of Doctor.Ru Internal Medicine, Vol. 20, No. 7 (2021), Published

Find original articles and reviews covering various aspects of rheumatology, pulmonology and the interview with Professor Alexander Mikhailovich Lila


1 July 09:54
A New Issue of Doctor.Ru Gynecology, Vol. 20 No. 6 (2021), Published

Find original articles and reviews covering various aspects of obstetrics, perinatology, gynecology and the interview with Professor Igor Yurievich Kogan

30 June 00:00
A New Issue of Doctor.Ru Neurology Psychiatry, Vol. 20, No. 5 (2021), Published

Find original articles and reviews covering various aspects of neurology, psychiatry and the interview with Professor Marina Arkadievna Kinkulkina

28 June 00:00
A New Issue of Doctor.Ru Internal Medicine, Vol. 20, No. 4 (2021), Published

Find original articles and reviews covering various aspects of cardiology, gastroenterology, internal medicine and the interview with Professor Elena Zelikovna Golukhova


All news